Prostate Adenocarcinoma
245
56
100
84
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
63 trials with published results (26%)
Research Maturity
84 completed trials (34% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
11.4%
28 terminated out of 245 trials
75.0%
-11.5% vs benchmark
7%
18 trials in Phase 3/4
75%
63 of 84 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 84 completed trials
Clinical Trials (245)
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam
Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
PSMA PET Response Guided SabR in High Risk Pca
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
Clinical Trial of Green Tea Catechins in Men on Active Surveillance
High-Risk prostatE Cancer radiatiOn Versus surgERy
Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy